CURACYTE AG has a total of 26 patent applications. Its first patent ever was published in 1999. It filed its patents most often in EPO (European Patent Office), Australia and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are CHEMOMAB LTD, LABRYS BIOLOGICS INC and AVIPEP PTY LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 6 | |
#2 | Australia | 5 | |
#3 | Canada | 5 | |
#4 | Germany | 4 | |
#5 | WIPO (World Intellectual Property Organization) | 4 | |
#6 | United States | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Acyclic or carbocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Schweinitz Andrea | 20 |
#2 | Steinmetzer Torsten | 20 |
#3 | Stuerzebecher Joerg | 14 |
#4 | Kuenzel Sebastian | 7 |
#5 | Giersiefen Helmut | 5 |
#6 | Sturzebecher Jorg | 5 |
#7 | Pamp Tanja | 5 |
#8 | Ohlmann Marion | 5 |
#9 | Stoeckel Johannes | 4 |
#10 | Kunzel Sebastian | 3 |
Publication | Filing date | Title |
---|---|---|
AU2002366874A1 | Modified tridegins, production and use thereof as transglutaminase inhibitors | |
DE10210590A1 | Inhibitors of coagulation factor Xa, their production and use | |
DE10210592A1 | New peptide derivatives used as urokinase inhibitors for therapy, prophylaxis or diagnosis of tumors, especially for reducing tumor metastasis | |
DE10163333A1 | Modified tridegins, their preparation, and their use as transglutaminase inhibitors and medicines and combination preparations containing them | |
DE10029015A1 | Coagulation Factor Xa inhibitor, useful for treatment, prophylaxis or diagnosis of thromboembolic disease, comprising acylated 3- or 4-amidino-benzylamine derivative | |
EP1104674A1 | O,o'-dihydroxy azo dyes as medicinal components with TPO-agonistic or -synergetic activity |